Absorption and Distribution of Glucosamine and Chondroitin

Condition	Intervention
Osteoarthritis	Drug: Glucosamine  Drug: Chondroitin

Osteoarthritis is the most common musculoskeletal disease in the world. While predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. Traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. The use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. This study will examine the pharmacokinetics of glucosamine and chondroitin.

This study consists of two phases. In Phase I, participants will have two study visits, during which multiple blood samples will be taken to determine levels of glucosamine and chondroitin found naturally in the body. During Phase II, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. Blood samples will be taken at each of the three Phase II study visits to examine the pharmacokinetics of glucosamaine and chondroitin.

Ages Eligible for Study:  21 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Inclusion Criteria:

• Able to walk

Exclusion Criteria:

• Allergy to glucosamine, chondroitin, or shellfish
• Liver or kidney disease
• Diabetes mellitus
• Concurrent use of other complementary or alternative therapies

Please refer to this study by ClinicalTrials.gov identifier  NCT00086229

Utah
      University of Utah Health Sciences Center, Salt Lake City,  Utah,  84132,  United States; Recruiting

Study ID Numbers:  1-R21-AT001938-01
Last Updated:  December 8, 2005
Record first received:  June 28, 2004
ClinicalTrials.gov Identifier:  NCT00086229
Health Authority: United States: Federal Government